BIOMAT Database Logo BIOMAT Database Logo

Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. 1995

S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Second Department of Internal Medicine, Yamanashi Medical University, Japan.

We investigated the antiarrhythmic effects of bidisomide (SC-40230), a new class I antiarrhythmic drug, in early-phase ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats. The effects of bidisomide were compared with those of mexiletine (MXT) and disopyramide (DSP), established class I antiarrhythmic drugs. Drugs were administered intravenously, 5 min before induction of coronary occlusion. Bidisomide (5 mg/kg) reduced the number of premature ventricular complexes and the incidence of ventricular tachycardia and ventricular fibrillation similarly to MXT and DSP in rats with ventricular arrhythmias induced by coronary artery occlusion. In rats with ventricular arrhythmias induced by coronary artery reperfusion following a 5-min coronary occlusion, the antiarrhythmic effects of 5 mg/kg of bidisomide were similar to those of the same doses of MXT and DSP. All three drugs significantly slowed the heart rate. Our results suggest that bidisomide may effectively reduce the severity of life-threatening ventricular arrhythmias that occur during acute coronary syndrome.

UI MeSH Term Description Entries
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D010880 Piperidines A family of hexahydropyridines.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004206 Disopyramide A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. Diisopyramide,Disopyramide Monohydrochloride,Disopyramide Phosphate,Disopyramide Phosphate (1:1),Disopyramide Phosphate (1:1), (+-)-Isomer,Disopyramide Phosphate (1:1), (R)-Isomer,Disopyramide Phosphate (1:1), (S)-Isomer,Disopyramide, (+-)-Isomer,Disopyramide, (R)-Isomer,Disopyramide, (S)-Isomer,Disopyramide, D-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:1), (R)-Isomer,Disopyramide, L-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:2), (+-)-Isomer,Disopyramide, L-Tartrate, (S)-isomer,Norpace,Palpitin,Palpitine,Rhythmodan,Ritmilen,Rythmilen,SC-13957,SC 13957,SC13957
D005117 Cardiac Complexes, Premature A group of cardiac arrhythmias in which the cardiac contractions are not initiated at the SINOATRIAL NODE. They include both atrial and ventricular premature beats, and are also known as extra or ectopic heartbeats. Their frequency is increased in heart diseases. Ectopic Heartbeats,Extrasystole,Premature Beats,Premature Cardiac Complexes,Cardiac Complex, Premature,Extrasystoles,Premature Cardiac Complex,Beat, Premature,Beats, Premature,Complexes, Premature Cardiac,Ectopic Heartbeat,Heartbeat, Ectopic,Heartbeats, Ectopic,Premature Beat,Premature Cardiac Complices
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic

Related Publications

S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
July 1994, Japanese journal of pharmacology,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Effects of HNS-32, a novel antiarrhythmic drug, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats.
February 2000, Molecular and cellular biochemistry,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Electrophysiologic effects of an antiarrhythmic agent, bidisomide, on sodium current in isolated rat ventricular myocytes: comparison with mexiletine and disopyramide.
May 2001, Japanese journal of pharmacology,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models.
February 1993, Molecular and cellular biochemistry,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Effect of mexiletine on reperfusion-induced ventricular arrhythmias: comparison with lidocaine.
November 1986, Archives internationales de pharmacodynamie et de therapie,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics.
April 1992, Clinical pharmacology and therapeutics,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats.
September 2003, Journal of pharmacological sciences,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Antiarrhythmic and antifibrillatory action of diltiazem on early and late phase ventricular arrhythmias following coronary artery occlusion and on reperfusion ventricular arrhythmias.
January 1986, Pharmacology,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds.
January 1983, British journal of clinical pharmacology,
S Komori, and S Sano, and B H Li, and K Matsumura, and A Naitoh, and S Mochizuki, and T Ishihara, and A Watanabe, and K Umetani, and H Ijiri
Coupling interval-related effects of class I antiarrhythmic drugs, mexiletine, cibenzoline and disopyramide, on ventricular activation in canine myocardial infarction.
December 1991, Japanese journal of pharmacology,
Copied contents to your clipboard!